NYSE - Nasdaq Real Time Price USD

Revvity, Inc. (RVTY)

94.42

-0.71

(-0.75%)

As of 1:38:44 PM EDT. Market Open.

Why Revvity (RVTY) Could Beat Earnings Estimates Again

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 1 hour ago

RVTY
-0.75%
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?

RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

Zacks 5 hours ago

RVTY
-0.75%
Revvity Board Declares Quarterly Dividend

WALTHAM, Mass., April 24, 2025--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.

Business Wire 21 hours ago

RVTY
-0.75%
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

BHC

RVTY
-0.75%
3 Cash-Producing Stocks Skating on Thin Ice

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

StockStory 2 days ago

SHW

RVTY
-0.75%
DE
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 4 days ago

RVTY
-0.75%
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing?

Revvity, Inc. ( NYSE:RVTY ) saw significant share price movement during recent months on the NYSE, rising to highs of...

Simply Wall St. 10 days ago

RVTY
-0.75%
Revvity to Hold Earnings Call on Monday, April 28, 2025

WALTHAM, Mass., April 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Business Wire 22 days ago

RVTY
-0.75%
FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo

The World Health Organization recognises the test as the “only” enzyme-linked immunospot-based interferon-gamma release assay.

Medical Device Network 22 days ago

RVTY
-0.75%
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

WALTHAM, Mass., April 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-

Business Wire 23 days ago

RVTY
-0.75%
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's strong product portfolio raises optimism about the stock.

Zacks 23 days ago

RVTY
-0.75%
1 Healthcare Stock to Target This Week and 2 to Turn Down

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.

StockStory 25 days ago

RVTY
-0.75%
GILD

JNJ
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Simply Wall St. 30 days ago

RVTY
-0.75%
Revvity Stock Tumbles Despite Expanding Genomics England Alliance

RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.

Zacks last month

RVTY
-0.75%
BSX

CAH
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

WALTHAM, Mass., March 20, 2025--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

Business Wire last month

RVTY
-0.75%
Revvity's (NYSE:RVTY) Solid Earnings Have Been Accounted For Conservatively

The market seemed underwhelmed by last week's earnings announcement from Revvity, Inc. ( NYSE:RVTY ) despite the...

Simply Wall St. last month

RVTY
-0.75%
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

WALTHAM, Mass., March 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum

Business Wire last month

RVTY
-0.75%
Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst performers in the research tools & consumables industry.

StockStory last month

RVTY
-0.75%
TECH
-1.54%
WAT
Revvity Full Year 2024 Earnings: In Line With Expectations

Revvity ( NYSE:RVTY ) Full Year 2024 Results Key Financial Results Revenue: US$2.76b (flat on FY 2023). Net income...

Simply Wall St. last month

RVTY
-0.75%
3 Reasons to Sell RVTY and 1 Stock to Buy Instead

Over the past six months, Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.

StockStory last month

RVTY
-0.75%

Performance Overview

Return	RVTY	S&P 500 (^GSPC)
YTD	-15.29%	-6.33%
1-Year	-7.28%	+9.13%
3-Year	-36.40%	+28.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Revvity, Inc. (RVTY)

Why Revvity (RVTY) Could Beat Earnings Estimates Again

Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?

Revvity Board Declares Quarterly Dividend

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

3 Cash-Producing Stocks Skating on Thin Ice

Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline

What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing?

Revvity to Hold Earnings Call on Monday, April 28, 2025

FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

1 Healthcare Stock to Target This Week and 2 to Turn Down

The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years

Revvity Stock Tumbles Despite Expanding Genomics England Alliance

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Revvity's (NYSE:RVTY) Solid Earnings Have Been Accounted For Conservatively

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks

Revvity Full Year 2024 Earnings: In Line With Expectations

3 Reasons to Sell RVTY and 1 Stock to Buy Instead

Performance Overview